Luigi Rossi
Formia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2026
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 23, 2025
Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.
Journal: The oncologist
Published: June 13, 2025
Clinical characteristics and Drug-Drug interactions in HER2+ breast cancer treated with T-DXd: Real-World data from the DE-REAL study.
Journal: The oncologist
Published: April 21, 2025
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.
Journal: Breast (Edinburgh, Scotland)
Published: October 22, 2024
First report of Central-line-associated bloodstream infection (CLAB- SI) due to Enterococcus raffinosus (ER) in a cancer patient.
Journal: La Clinica terapeutica
Published: December 04, 2023
Psoriasis induced by first‑line pembrolizumab in metastatic non‑small cell lung cancer: A case report.
Journal: Oncology letters
Published: January 04, 2023
Undertreatment with Osimertinib in patient with multiple chemical sensitivity. A case report.
Journal: La Clinica terapeutica
Published: November 14, 2022
What hides beneath the scar: sexuality and breast cancer what women don't say: A single-center study.
Journal: La Clinica terapeutica
Published: July 20, 2022
Last Updated: 09/26/2026